Systemic mastocytosis (SM) is characterized by an abnormal accumulation of mast cells, a type of immune cell present throughout the body that contributes to allergic and inflammatory responses ...

Indolent systemic mastocytosis (ISM) is one of the five subtypes of systemic mastocytosis, a condition characterized by the ...

Blueprint Medicines' strong pipeline and Ayvakit growth make it promising. Read why BPMC stock is rated "Hold" due to high ...

In a study of 116 patients with systemic mastocytosis (SM), a rare mast cell disease, about 1 in 5 participants progressed to an advanced form of SM, incurring greater healthcare costs along the way.

Further testing led to a surprising diagnosis of systemic mastocytosis (SM), a rare blood disorder that causes certain immune cells, called mast cells, to build up in different parts of the body.

Healthcare Analysts provide expert insights on current and emerging treatments for Systemic Mastocytosis (relevant companies Blueprint ...

A study shows that high-grade glioma tumor cells harboring DNA alterations in the gene PDGFRA responded to the drug avapritinib, which is already approved by the United States Food and Drug ...

(Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced expanded clinical results from the Open Label Extension (OLE) ...